Rapamycin and the Dog Aging Project: the trial humans are not getting

What the Dog Aging Project actually is

The Dog Aging Project is a long-term study of aging in companion dogs, centered at the University of Washington and running since 2014 across a network of veterinary schools. Most of it is observational: an enormous cohort of pet dogs whose owners contribute health, activity and environment data over years.^[1]

Inside that cohort sits the interventional piece, the Test of Rapamycin in Aging Dogs. That trial is where the drug appears, and it is the part that matters for anyone reading about rapamycin and longevity.

What TRIAD is testing

Strong human evidence The published design describes a parallel-group, double-masked, randomized, placebo-controlled multicenter trial testing whether the drug prolongs lifespan and improves several healthspan measures in healthy middle-aged dogs recruited from the wider project.^[2] Enrollment runs through participating veterinary schools, with dogs generally seven years or older and above a minimum weight.^[3]

Read the design carefully and you see what is unusual about it. Randomized, placebo-controlled and masked removes the expectation effects that ruin self-reported longevity data. Multicenter removes single-site quirks. And the primary endpoint is survival, not a biomarker standing in for survival. Almost nothing in human longevity research meets that description.

Why dogs are the right animal

Mice are convenient and distant. They live in controlled facilities, eat standardized chow, and have metabolic rates several times ours. Every mouse lifespan result carries an unstated translation problem, including the landmark rapamycin result that started the field.^[4]

Companion dogs sit much closer. They breathe the same indoor air, share the same sofa, develop age-related cancer, arthritis, cognitive decline and heart disease that look like ours, and vary in size and genetics the way a real population does. Their lifespan is short enough that a survival trial can actually finish. As a bridge between rodent work and human medicine, it is hard to design anything better.

Dogs age very much like we do, they just do it seven to 10 times faster.

What the pilot trial found

Limited evidence Before the main trial, a randomized controlled study of short-term dosing in older dogs reported improvements in echocardiographic measures of cardiac function, including fractional shortening and ejection fraction, with no clinical side effects compared with placebo.^[5]

That is a genuinely encouraging safety and feasibility signal, and it is worth being precise about its limits. Small sample, ten weeks, surrogate cardiac measures rather than survival or disease incidence. It justified running the larger trial. It did not preempt its result.

The funding crisis nobody expected

In early 2025 the project came close to ending. Federal support lapsed and the trial was at real risk before a seven million dollar private grant arrived to continue it.^[6] Veterinary trade coverage at the time described the grant explicitly as a rescue.

That episode says something about the field. A study whose value depends entirely on running to completion is exactly the kind that conventional grant cycles handle badly. Long-horizon aging research is structurally fragile, which is one reason so much of the evidence base is short-term surrogate measures rather than survival.

Can I get rapamycin for my dog?

Only from a veterinarian, off-label, as an unapproved use in that species. Some practices will prescribe it and some compounding pharmacies dispense it, and there is a visible market of owners doing this outside any trial.^[7]

The argument against is the same one that applies to humans, only sharper: the trial exists because the answer is unknown, the animal cannot consent, and dosing outside the study generates no data for anyone. Our page on rapamycin for dogs goes through the veterinary picture, including what is known about tolerability.

You have to approach it very much like a pediatric clinical trial.

What this trial means for people

If the dogs live longer, it becomes the first controlled survival result for this drug in a large, genetically diverse mammal sharing our environment. That would be the strongest evidence the field has ever had, and it would still not be a human result.

If they do not, it would be the most informative negative in the field, and considerably more decisive than anything the current human self-experimentation can produce. Either way, the contrast is uncomfortable: the dogs are enrolled in a designed trial with a survival endpoint while the humans taking the same compound have no control group, no registry and no endpoint. Our main evidence guide and our page on what the dose changes cover the human side of that gap.

Frequently asked questions

Can rapamycin help dogs with aging?

That is the question the trial exists to answer, and it has not been answered. The Test of Rapamycin in Aging Dogs is a randomized, placebo-controlled, multicenter trial testing whether the drug prolongs lifespan and improves healthspan measures in healthy middle-aged dogs. Until it reports, the honest answer is that nobody knows.

Is the Dog Aging Project legitimate?

Yes. It is a long-term study of canine aging centered at the University of Washington, founded in 2014, running through university veterinary schools with published protocols and peer-reviewed design papers. Its funding has been precarious, which is a different problem from legitimacy.

What are the side effects of rapamycin in dogs?

The 2017 pilot trial of short-term dosing reported no clinical side effects compared with placebo. That was a small study over ten weeks, so it establishes short-term tolerability rather than long-term safety, which is precisely what the larger trial is designed to measure.

Can I get rapamycin for my dog?

Only through a veterinarian, as an off-label prescription. Some veterinary practices will write for it and some compounding pharmacies dispense it. It is not an over-the-counter product and it is not approved for use in dogs by any regulator.

Why test the drug in dogs at all?

Because dogs are an unusually good model. They live in human homes, share our environment, develop the same age-related diseases, and have a lifespan short enough that a trial can finish. A mouse result is far from a person. A dog result is closer.

What did the earlier pilot study find?

A randomized controlled trial of short-term dosing in older dogs reported measurable improvements in echocardiographic measures of heart function, including fractional shortening and ejection fraction, alongside no clinical adverse effects. Interesting, small, and not a lifespan result.

How long will the trial take?

Years. Lifespan is the primary endpoint in dogs that begin the trial in middle age, which means the study runs until enough of the cohort has been followed to the end of life. That timeline is why interim healthspan measures matter so much.

Which dogs qualify?

Broadly, healthy companion dogs at least seven years old, above a minimum weight, enrolled through participating veterinary schools. Eligibility criteria and enrollment status are set by the project itself and change over time.

Did the project nearly shut down?

It came close. Federal funding lapsed and the trial was at genuine risk before a seven million dollar private grant rescued it in early 2025. That episode is a reminder that long-horizon aging research is fragile in a way short-horizon research is not.

Does a dog result apply to people?

Better than a mouse result and not automatically. Dogs share our environment and disease profile, which removes some of the objections to rodent work. They are still a different species with different metabolism, and dose translation remains an assumption.

What dose do the dogs receive?

Low intermittent dosing rather than the daily immunosuppressive regimen, following the same reasoning as human off-label use. Specific amounts are set by protocol and body weight, and are a matter for the trial and for any prescribing veterinarian rather than for owners.

Are there results yet?

No lifespan results. Design and rationale papers are published, the pilot work is published, and interim healthspan analyses are expected before any survival conclusion. Anyone claiming the project has already shown dogs living longer is ahead of the data.

Should I give my healthy dog rapamycin now?

That is a conversation with a veterinarian who knows the animal, not a decision to make from a webpage. The case for waiting is straightforward: the trial exists because the answer is unknown, and giving an unapproved immunosuppressant to a healthy animal outside a trial produces no data and carries real risk.

How is this different from human rapamycin use?

It is more rigorous. The dogs are in a randomized, placebo-controlled, double-masked trial with a lifespan endpoint. The humans taking it are an uncontrolled, unregistered group with no endpoint at all. The animals are getting better science than the people.